Matzkin Elizabeth G, Curry Emily J, Kong Qingwu, Rogers Miranda J, Henry Michael, Smith Eric L
From the Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA (Dr. Matzkin), the Department of Orthopaedic Surgery, Boston Medical Center, Boston (Ms. Curry and Dr. Smith), and the Department of Orthopaedic Surgery, Tufts University School of Medicine, Boston (Dr. Kong, Dr. Rogers, and Dr. Henry).
J Am Acad Orthop Surg. 2017 Oct;25(10):703-714. doi: 10.5435/JAAOS-D-16-00541.
Intra-articular corticosteroid injections are often used for short-term pain relief in patients with knee osteoarthritis (OA). This study investigates the efficacy of intra-articular corticosteroid injections in patients with symptomatic knee OA and factors that affect treatment response.
This prospective, multicentered cohort study had 100 participants with radiographic evidence of knee OA enrolled. Participants received one corticosteroid injection into the affected knee and were evaluated before the injection (baseline) and at 3 weeks, 6 weeks, 3 months, and 6 months after the injection.
Participants' Visual Numeric Scale and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores improved at all time points except for the Visual Numeric Scale score at 6 months, compared with baseline scores (P < 0.001). Participants with Kellgren-Lawrence grade 1 or 2 OA saw clinical improvement in the WOMAC scores at all time points, compared with the baseline score (P < 0.01). Compared with all other subgroups, obese patients with Kellgren-Lawrence grade 3 or 4 OA had significantly worse WOMAC scores at baseline, 6 weeks, and 3 months (P < 0.01 and P < 0.01, respectively).
Our findings validate previously established guidelines for nonsurgical management of knee OA and suggest that intra-articular corticosteroid injections may be an acceptable short-term management option in patients unwilling or unable to undergo surgical treatment. Obesity and OA severity affect the efficacy of intra-articular corticosteroid injections.
Patients receiving intra-articular corticosteroid injections had improved pain and function. Clinicians should expect less improvement in patients with obesity and/or advanced arthritis. Clinical benefits of intra-articular injections in these patients are less predictable.
关节内注射皮质类固醇常用于缓解膝关节骨关节炎(OA)患者的短期疼痛。本研究调查了关节内注射皮质类固醇对有症状的膝关节OA患者的疗效以及影响治疗反应的因素。
这项前瞻性、多中心队列研究纳入了100名有膝关节OA影像学证据的参与者。参与者在患侧膝关节接受一次皮质类固醇注射,并在注射前(基线)以及注射后3周、6周、3个月和6个月进行评估。
与基线评分相比,除6个月时的视觉数字评分外,参与者的视觉数字评分和西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分在所有时间点均有所改善(P < 0.001)。与基线评分相比,Kellgren-Lawrence 1级或2级OA患者的WOMAC评分在所有时间点均有临床改善(P < 0.01)。与所有其他亚组相比,Kellgren-Lawrence 3级或4级OA的肥胖患者在基线、6周和3个月时的WOMAC评分明显更差(分别为P < 0.01和P < 0.01)。
我们的研究结果验证了先前确立的膝关节OA非手术治疗指南,并表明关节内注射皮质类固醇可能是不愿或无法接受手术治疗的患者可接受的短期治疗选择。肥胖和OA严重程度会影响关节内注射皮质类固醇的疗效。
接受关节内注射皮质类固醇的患者疼痛和功能得到改善。临床医生应预期肥胖和/或晚期关节炎患者的改善较少。关节内注射对这些患者的临床益处较难预测。